Announced the latest prices for a box of different versions of evantumumab?

Evantumumab is a targeted therapy for adult non-small cell lung cancer (NSCLC) patients carrying EGFR exon 20 insertion mutations. Through its unique bispecific antibody design, it simultaneously targets two key oncogenic drivers, EGFR and MET, demonstrating excellent efficacy in specific types of lung cancer. As the first targeted drug approved to treat this type of mutated lung cancer, the emergence of evantumumab undoubtedly provides patients with a new treatment option.

Prices of different versions of evantumumab

Currently, there is only one version of on the market, and other versions such as its generic version are not yet on the market. In China, evantumumab has not yet been officially launched, but the price dynamics of the drug can be learned through overseas drug purchase channels. The price of the original drug Evantumumab 350mg/7ml produced by Janssen Pharmaceuticals in the United States is approximately $10,300. Compared with other quotes in the international market, this price shows that the cost for Chinese patients to obtain the drug through specific channels is relatively low. However, since it is not marketed in China, patients need to pay attention to the legality and safety of the source of the drug when purchasing it, as well as consider international logistics and potential legal risks.

Factors affecting price

The high price of evantumumab is mainly affected by several factors, such as research and development costs, production complexity, market exclusivity, patent protection period, as well as drug pricing policies and medical insurance coverage in different countries and regions. As an originator drug for which biosimilars have not yet been released, its price usually remains high during the patent protection period.

Although the current price of evantumumab is a significant burden for most patients, with the development of the drug life cycle, possible future biosimilar competition, adjustments to medical insurance policies, and patient assistance programs of pharmaceutical companies may have a positive impact on the affordability of the drug. In addition, global health organizations and governments are constantly exploring mechanisms to accelerate the introduction of innovative drugs, striving to balance the contradiction between innovation and accessibility. It is recommended that patients consult a doctor in advance before purchasing drugs, eliminate contraindications under the guidance of a doctor, and follow the doctor's instructions for treatment.